Simranjit Singh highlights Guardant Health’s role in the global precision oncology landscape and how the company leverages its proprietary blood tests, vast data sets, and advanced analytics across the huge AMEA region. Singh also touches on the significance of a recent US FDA approval for its comprehensive liquid biopsy and talks growth plans, target markets, and adoption challenges.
Regulators are in a difficult position and still coming to understand how to define these new technologies. Greater alignment with the US does seem to be the most beneficial way forward and we will increasingly see greater pathway harmonisation across regions
